USP Standards For Biological Drugs Would Restrict Innovation, US FDA Says

 
• By Bowman Cox
  
FDABldg1ExteriorWithCircle_1200x675
FDA officials present their argument against USP monographs for biologics.
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Manufacturing

More from Compliance